2005, Number 4
<< Back Next >>
Ann Hepatol 2005; 4 (4)
A new insight into the differences among non-cirrhotic and cirrhotic patients using the liver disease quality of life instrument (LDQOL)
Dias TMC, Gomes de SRMF, Strauss E
Language: English
References: 20
Page: 264-271
PDF size: 68.79 Kb.
Text Extraction
Our aims were to validate the Brazilian Portuguese version of the Liver Disease Quality of Life Questionnaire instrument (LDQOL1.0) and evaluate this tool in non-cirrhotic patients.
Methods: The LDQOL1.0 consists of the SF-36 generic measure of health-related quality of life (HRQOL) and 12 disease-specific dimensions for patients with liver disease. The Brazilian Portuguese version instrument was administered to 103 patients with liver disease. Reliability was analyzed by studying the internal consistency of the individual disease-specific dimensions of the LDQOL, as well as by studying the test-retest reliability in a sub-group of 74 patients who completed the questionnaire on two occasions 1 to 2 weeks apart. Validity was analyzed by determining the instrument’s ability to discriminate between groups of patients according to severity of the liver disease.
Results: Internal consistency in the disease-specific dimensions was good (CACs 0.66-0.94), as well as test-retest reliability in all dimensions (ICCs of 0.64-0.96) p ‹ 0.05. We found statistically significant differences in six domains when compensated cirrhotic patients, Child A, were compared with non-cirrhotic patients. We also found statistically significant differences when we compared cirrhotic patients evaluated assessed by Child-Pugh and Meld classifications. Patients with Child C and Meld ≥ 15 showed worse quality of life. Moderate ceiling and floor effects were found in some disease-specific dimensions. In
Conclusions: the Brazilian Portuguese version of the LDQOL 1.0 is very useful for measuring HRQOL in liver diseases.
REFERENCES
Leplège A, Hunt S. The problem of quality of life in medicine. JAMA 1997; 278: 47-50.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995; 273: 50-65.
Cirrincione R, Taliani G, Caporaso N, Mele A, et al. Quality of life assessment in chronic liver, disease. Hepato-Gastroenterol 2002; 49: 813-816.
Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, Kim S, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gastroenterol 2000; 95(12): 3552-65.
Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
Bonkovsky HL, Wooley JM. Reduction of health-realted quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-270.
Teixeira MCD, Strauss E. Tool to evaluate quality of life in patients with liver diseases- LDQOL 1.0 (Liver Disease Quality of Life). Translation and adaptation into Portuguese language. GED Portuguese 2004; 23(6): 255-259.
Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR, et al. Brazilian Portuguese version of the SF 36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol Portuguese 1999; 39(3): 143-150.
Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-32.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R, et al. Transection of the esophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2): 464-70.
Gayotto LCC e Comitê SPH/SBH. Visão histórica e Consenso Nacional sobre a classificação das hepatites crônicas. GED 2000; 19(3): 137-140.
Nunnally J, Berstein IH. Psychometric Theory. 3rd ed. New York : McGraw-Hill; 1994: xx20.
Younossi ZM, Guyatt G. Quality of life assessments and chronic liver disease. Am J Gastroenterol 1998; 93: 1037-41.
Petrou S. Measurement and application of health-related quality of life in chronic viral hepatitis. Viral Hepatitis Rev 1997; 3: 253-65.
Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health-related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 39-55.
Casanovas T, Vallejo G, Herdman M, Casado A, Ribas S, et al. Validation of the Spanish Version of the Liver Disease Quality Of Life questionnaire in transplant patients. Transplantation Proc 2003; 35: 1803-05.
Bagheri H, Fouladi A, Barange K, Lapeyre-Mestre M, Payen JL, Montastruc JL, Vinel JP, et al. Follow-up of adverse drug reactions from peginterferon alfa-ribavirin therapy. Pharmacotherapy 2004; 24(11): 1546-53.
Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39(1 Suppl): S23-7.